A Phase 1/2 Study of AZD0305 to Treat Multiple Myeloma

Full Title

A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants with Relapsed or Refractory Multiple Myeloma

Purpose

Researchers want to find the best dose of AZD0305 to use in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. AZD0305 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have multiple myeloma that came back or keeps growing after at least 3 prior regimens of anti-cancer therapy.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Sridevi Rajeeve’s office at 646-608-4310.